Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes.
Gillette-Guyonnet
Sophie
S
Andrieu
Sandrine
S
Nourhashemi
Fati
F
Reynish
Emma
E
Vellas
Bruno
B
D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil